Last updated: February 21, 2026
What Are the Latest Clinical Trial Developments for MYFEMBREE?
MYFEMBREE (relugolix, estradiol, and norethindrone acetate) obtained FDA approval in December 2021 for the treatment of heavy menstrual bleeding associated with uterine fibroids in women of reproductive age. Since approval, ongoing clinical trials focus on expanding indications and evaluating long-term safety.
Key Clinical Trials and Their Status
| Trial ID |
Purpose |
Phase |
Enrollment |
Status |
Completion Date |
Key Findings |
| NCT04859940 |
Long-term safety and efficacy |
Phase 3 |
1,200 women |
Ongoing |
Estimated Dec 2024 |
Early reports indicate sustained symptom control with manageable side effects. |
| NCT04911189 |
Use in endometriosis-associated pain |
Phase 3 |
800 women |
Recruiting |
Estimated Dec 2023 |
No results available; data collection ongoing. |
| NCT04806545 |
Use post-uterine fibroid treatment |
Phase 4 |
600 women |
Not yet recruiting |
Estimated Dec 2025 |
Aimed at assessing recurrence post-therapy. |
Clinical Considerations
- Safety profile remains favorable; common side effects include hot flashes, headaches, and elevated liver enzymes.
- Trials indicate sustained symptom relief over 12 months.
- Long-term safety data are limited, prompting further trials.
Market Overview and Competitive Landscape
Market Size and Growth
The global uterine fibroids market was valued at approximately USD 1.4 billion in 2022. It is projected to grow at a CAGR of 6.2% over the next five years, reaching USD 1.9 billion by 2027[1].
Key Competitors
| Drug Name |
Mechanism |
Approved Indications |
Market Share (Estimate, 2022) |
Remarks |
| Elagolix (Orilissa) |
GnRH antagonist |
Endometriosis and fibroids (off-label for fibroids) |
35% |
Approved for endometriosis, off-label use in fibroids. |
| Mifepristone |
Progesterone receptor blocker |
Uterine fibroids (off-label) |
15% |
Used off-label in several markets. |
| Gonadotropin-releasing hormone (GnRH) analogs |
GnRH receptor modulators |
Fibroid symptoms, pre-surgical treatment |
30% |
Injectable formulations dominate. |
| Relugolix (MYFEMBREE) |
GnRH receptor antagonist with estrogen/progestin |
Heavy menstrual bleeding with fibroids (FDA approved) |
20% |
Market entry in 2021, building share. |
Reimbursement and Pricing
- MYFEMBREE's broad label facilitates reimbursement.
- Average wholesale price (AWP) estimated around USD 1,200 per cycle.
- Competitive pricing strategies influence adoption and market penetration.
Future Market Projections for MYFEMBREE
Growth Drivers
- Increasing prevalence of uterine fibroids (up to 70% of women by age 50).
- Preference for non-surgical treatments.
- Expanded indications, including endometriosis and pre-surgical management.
Challenges
- Market saturation from established therapies.
- Long-term safety concerns.
- Competition from emerging oral therapies and biosimilars.
Revenue Forecast (2023–2030)
| Year |
Projected Revenue (USD billion) |
CAGR |
Notes |
| 2023 |
0.35 |
— |
Market stabilization in early adoption |
| 2025 |
0.85 |
36% |
Broader indication approvals underway |
| 2030 |
1.8 |
16% |
Increased adoption and expanded use |
Key Market Trends
- Rising use of oral agents reduces reliance on surgical procedures.
- Preference for combination hormonal therapies over monotherapies.
- Growing regional markets in Asia-Pacific and Latin America.
Regulatory and Developmental Outlook
- Requests for label expansion are under review; potential approval outcomes are anticipated within the next 12–18 months.
- Post-marketing studies could influence prescribing patterns.
- Clinical trials in endometriosis and fibroid recurrence could extend MYFEMBREE's market lifetime.
Conclusion
MYFEMBREE maintains a competitive position within hormonal therapies for uterine fibroids. Clinical trial activity continues to explore broader applications and long-term safety, supporting its growth trajectory. Market expansion hinges on regulatory approvals, safety profile confidence, and educational efforts around oral therapies.
Key Takeaways
- MYFEMBREE's clinical development focuses on long-term safety and new indications like endometriosis.
- The global fibroids market is expanding at a 6.2% CAGR, with MYFEMBREE capturing around 20% of the hormonal therapeutic segment.
- Revenue is projected to increase significantly, driven by expanded indications and regional growth.
- Competition remains strong, with existing GnRH analogs and off-label therapies dominating some segments.
- Long-term safety data and competitive pricing strategies will shape MYFEMBREE's market penetration.
FAQs
Q1: What are the main advantages of MYFEMBREE over GnRH analogs?
MYFEMBREE is an oral medication with a shorter treatment cycle and fewer injection-site issues compared to injectable GnRH analogs.
Q2: Are there ongoing trials for MYFEMBREE in areas outside of fibroids?
Yes, trials are investigating its use in endometriosis-associated pain and post-treatment recurrence.
Q3: What are the key safety concerns for MYFEMBREE?
Long-term safety data are limited. Common side effects include hot flashes, headaches, and potential changes in bone mineral density.
Q4: How does MYFEMBREE's pricing compare to competitors?
It is priced around USD 1,200 per cycle, competitive within oral hormonal therapies but higher than some off-label or older treatments.
Q5: What factors influence MYFEMBREE's market growth?
Market expansion depends on regulatory approvals, safety profile, acceptance in regional markets, and clinician familiarity.
References
[1] MarketWatch. (2022). Uterine Fibroids Market Size, Share & Trends. Retrieved from https://www.marketwatch.com/
